On September 5, 2018 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, reported that it will present data on its investigational anti-PD-1 antibody tislelizumab at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC), which takes place September 23-26 in Toronto, Canada (Press release, BeiGene, SEPT 5, 2018, View Source;p=irol-newsArticle&ID=2366246 [SID1234529293]). Discovered by BeiGene, tislelizumab is being studied as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumors and hematologic cancers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentations:
Title: Tislelizumab Combined with Chemotherapy as First-Line Treatment in Chinese Patients with Advanced Lung Cancer
Session 1: JCSE01 – Perspectives for Lung Cancer Early Detection
Location: Room 202 BD
Date: Sunday, September 23
Time: 07:30-11:15 EDT
Presenter: J. Wang
Poster: P1.04-36
Session 2: P1.04 Immuno-oncology
Date: Monday, September 24
Time: 16:45-18:00 EDT
Presenter: J. Wang
Title: Preliminary Results with Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC)
Poster: P2.04-29
Session: P2.04 Immuno-oncology
Date: Tuesday, September 25
Time: 16:45-18:00 EDT
Presenter: Y-L. Wu
About Tislelizumab
Tislelizumab (BGB-A317) is an investigational humanized monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors. Discovered by BeiGene scientists in Beijing, tislelizumab is designed to bind to PD-1, a cell surface receptor that plays an important role in downregulating the immune system by preventing the activation of T-cells. Tislelizumab has demonstrated high affinity and specificity for PD-1. It is potentially differentiated from the currently approved PD-1 antibodies in an engineered Fc region, which is believed to minimize potentially negative interactions with other immune cells, based on preclinical data. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene Corporation have a global strategic collaboration for the development of tislelizumab in solid tumor cancers outside of Asia (except Japan).